VRCA (Verrica Pharmaceuticals Inc.) חוב לטווח קצר להון

This Verrica Pharmaceuticals (VRCA) price chart illustrates the biopharmaceutical business's potential for the global rollout of high-premium innovative skin virus medications. The current metric stands at 0.23. Stable cash flow and high margins are based on exclusive patents. Meanwhile, the company relies on a loyal staff of experts and commercial leaders, retaining key personnel through stock options.

The automation of applicator assembly lines and the digitalization of warehouses at Verrica Pharmaceuticals (VRCA) are optimizing operating expenses, thereby influencing the current financing structure. The short-term debt-to-equity ratio measures the rate of change in debt load relative to the business's market value, which allows this short-term liabilities-to-equity chart to assess the balance between the issuer's financial stability and the risk of aggressive borrowing.